The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 24th 2025
A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for Cancer Research annual meeting runs April 25-30, with the key presentations coming Sunday through Tuesday.
FDA Approves Tisa-Cel for Third Indication, R/R Follicular Lymphoma
May 31st 2022Tisagenlecleucel (tisa-cel) was approved to treat adults with relapsed or refractory (R/R) follicular lymphoma. This is the third indication for the therapy since it became the first FDA-approved chimeric antigen receptor T-cell therapy in 2017.
Read More
Fully Artificial Pancreas Produces Results Comparable With Hybrid Artificial Pancreas
May 31st 2022This new study from Canada compared outcomes in patients living with type 1 diabetes who used 2 closed-loop insulin delivery systems: a fully artificial pancreas that did not require meal input and a hybrid artificial pancreas that required carbohydrate counting.
Read More
Genetic Risk Scores for Alzheimer Disease May Have Implications for Parkinson Disease
May 30th 2022The findings from the study indicate that higher genetic risk score for Alzheimer disease (AD) are associated with cognitive declines in patients with Parkinson disease (PD), while higher genetic risk scores for PD signify an increased risk of PD, albeit with slower clinical progression after diagnosis.
Read More
Study Finds Adjuvant Therapy Beneficial for Distal Cholangiocarcinoma With Lymph Node Metastasis
May 29th 2022Recurrence is common in patients with distal cholangiocarcinoma, even after curative surgical resection. In a recent study, postoperative adjuvant therapy correlated with improved survival, but only in certain patients.
Read More
Nivolumab-Based Combos Approved in First-line Advanced ESCC
May 28th 2022The approvals were announced by Bristol Myers Squibb (BMS), maker of the 2 immunotherapy treatments approved for 1 combination: nivolumab (Opdivo), the first approved PD-1 immune checkpoint inhibitor, and ipilimumab (Yervoy), which activates the immune system by targeting CTLA-4.
Read More
Increased Social Spending by States Linked to Improved OS for Black Patients With Cancer
May 26th 2022Data to be presented next week during the American Society of Clinical Oncology Annual Meeting show that for every 10% increase in public welfare spending, there was a 4.55% narrowing of the 5-year overall survival (OS) disparity between Black and White patients with cancer.
Read More